Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus (SOLEIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00752999
Recruitment Status : Withdrawn (Study was withdrawn for business reasons before study start.)
First Posted : September 16, 2008
Last Update Posted : April 30, 2012
Information provided by (Responsible Party):
Rigel Pharmaceuticals

Brief Summary:
Approximately 225 patients meeting study entry requirements will be enrolled and randomized (2:1, active versus placebo superimposed on background treatment) to R788 or placebo. Patients will be followed for efficacy and safety parameters for 6 months. The investigator should taper corticosteroids if clinically warranted.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Fostamatinib Disodium (R935788) Drug: Placebo Phase 2

Detailed Description:
This study is a multi-center, multinational, randomized, double-blind, placebo-controlled Phase II clinical trial. Study enrollment will comprise approximately 225 patients meeting study inclusion requirements. The study will be conducted at up to 80 multinational investigational sites. Eligible patients will be randomized (2:1) into one of two 6 month treatment groups. One group (approximately 150 patients) will receive R788 150 mg PO bid; the other treatment group (approximately 75 patients) will receive placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease
Study Start Date : November 2008
Estimated Primary Completion Date : November 2009
Estimated Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Arm Intervention/treatment
Experimental: A
150 mg tablet, oral, twice-a-day
Drug: Fostamatinib Disodium (R935788)
150 mg tablet, oral, twice-a-day
Other Name: R788

Placebo Comparator: B
Placebo tablet, oral, twice-a-day
Drug: Placebo
Placebo tablet, oral, twice-a-day

Primary Outcome Measures :
  1. The primary efficacy endpoint is defined as the decrease from baseline in the SELENA-SLEDAI score at 6 months. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Composite Responder analysis defined as ≥4 points improvement in SELENA-SLEDAI and no 'Severe SLE flare' after Week 6. No worsening (≤10 mm on VAS) of Physician Global Assessment, or, no worsening of SF 36 PCS (not >-0.8) or PFI (not >2.5) [ Time Frame: 3 and 6 months ]
  2. Attainment of daily prednisone dose decrease in those patients on daily corticosteroids by 50% or to ≤ 7.5 mg prednisone (or equivalent for other corticosteroids) at 3 and 6 months. [ Time Frame: 3 and 6 months ]
  3. Decrease from baseline in SELENA-SLEDAI score at each post baseline visit. [ Time Frame: At each post baseline visit ]
  4. Attainment of improvement in SELENA-SLEDAI by ≥ 2 points at Weeks 2 and 4. [ Time Frame: Weeks 2 and 4 ]
  5. Attainment of improvement in SELENA-SLEDAI by ≥ 4 points at each post baseline visit. [ Time Frame: At each post baseline visit ]
  6. Change from baseline of Physician Global Assessment by VAS over 6 months. [ Time Frame: 6 months ]
  7. Time to rescue medication. [ Time Frame: At each post baseline visit ]
  8. Time to severe SLE flare by SELENA Flare Index. [ Time Frame: At each post baseline visit ]
  9. Change from baseline in the component scores of the SF 36 at Month 3 and Month 6. [ Time Frame: Month 3 and 6 ]
  10. Effects on liver function tests, clinically significant reductions in peripheral neutrophil counts, G-I adverse effects, new onset or aggravated hypertension, and other adverse effects as they may appear. [ Time Frame: At each post baseline visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must give written informed consent to participate in this study by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.
  • Males and females, 18 years of age or older, with active SLE diagnosed at least 6 months prior to Day 1 dosing. Active SLE is defined as having fulfilled the ACR criteria for SLE.
  • Patients of childbearing potential must be fully informed of the potential for R788 to adversely affect the fetus and, if sexually active, must agree to use an effective method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent).
  • The patient must otherwise be in good health as determined by the investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period.
  • In the investigator's opinion, the patient has the ability to understand the nature of the study and any anticipated risks of participation, communicate satisfactorily with the investigator, and participate in and comply with the requirements of the entire protocol.

Exclusion Criteria:

  • The patient has a history of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study.
  • Clinically significant or uncontrolled medical disease in any organ system, other than due to SLE.
  • Background immunosuppressive therapy that has not remained stable ≤ 4 weeks prior to baseline.
  • Severe active or unstable renal disease.
  • Active severe neuropsychiatric SLE.
  • Female patients must not be breastfeeding and must have a negative urine pregnancy test per the Schedule of Study Activities.
  • The patient has a history of substance abuse, drug addiction, or alcoholism.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00752999

Sponsors and Collaborators
Rigel Pharmaceuticals
Layout table for investigator information
Study Director: Daniel B. Magilavy, MD Rigel Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Rigel Pharmaceuticals Identifier: NCT00752999    
Other Study ID Numbers: C-935788-015
2008-004472-50 ( EudraCT Number )
First Posted: September 16, 2008    Key Record Dates
Last Update Posted: April 30, 2012
Last Verified: April 2012
Keywords provided by Rigel Pharmaceuticals:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases